Claim Amendments

Please cancel claims 21, 23, and 27 without prejudice, and please amend claims 1, 4-10, 13, 15, 18, 21, 22, 26, 32-34, 36, 37, and 40-42, as follows. This listing of claims will replace all prior versions and listings of claims in the instant application.

Listing of Claims:

1. (Currently Amended) An antimicrobial sulfonamide derivative, or a salt or a hydrate thereof, comprising:

a core cyclic peptide or core antibiotic of a lipopeptide antibiotic; and

a lipophilic moiety,

wherein said lipophilic moiety is covalently attached to the core cyclic peptide or core ~~cyclic~~ antibiotic *via* a linking chain which includes a sulfonamide linkage and wherein said core cyclic peptide or core antibiotic is not of laspartomycin or polymyxin.

2. (Original) The antimicrobial sulfonamide derivative, salt or hydrate of Claim 1 in which the linking chain is a sulfonamide linkage.

3. (Original) The antimicrobial sulfonamide derivative, salt or hydrate of Claim 1 in which the linking chain is a linker that links the core cyclic peptide or core antibiotic to the lipophilic moiety.

4. (Currently Amended) The antimicrobial sulfonamide derivative, salt or hydrate of Claim 1 which is a compound according to structural Formula (I):

(I) $Y\text{-}X\text{-}N(R^4)(\text{-}L\text{-}X\text{-}N(R^1))_m\text{-}R$

wherein:

Y is a lipophilic moiety;

~~Each~~ each X is independently selected from the group consisting of -co-SO2-, -CS-, -PO-, -OP(O)-,-OC(O)-, -NHCO and ~~-N(R[4])CO-~~ -N(R[4])CO- with the proviso that at least one X is -SO2-;

M is 0 or 1;

L is a linker;

N is nitrogen;

R^1 and R^4 are each independently selected from the group consisting of hydrogen, (C_1-C_{25}) alkyl optionally substituted with one or more of the same or different R^2 groups, (C_1-C_{25}) heteroalkyl optionally substituted with one or more of the same or different R^2 groups, (C_5-C_{30}) aryl optionally substituted with one or more of the same or different R^2 groups, (C_5-C_{30}) arylaryl optionally substituted with one or more of the same or different R^2 groups, (C_5-C_{30}) biaryl optionally substituted with one or more of the same or different R^2 groups, five to thirty membered heteroaryl optionally substituted with one or more of the same or different R^2 groups, (C_6-C_{30}) arylalkyl optionally substituted with one or more of the same or different R_2 groups and six to thirty membered heteroarylalkyl optionally substituted with one or more of the same or different R_2 groups;

each R^2 is independently selected from the group consisting of $-OR^3$, $-SR^3$, $-NR^3R^3$, -CN, $-NO_2$, $-N^3$, $-C(O)OR^3$, $-C(O)NR^3R^3$, $-C(S)NR^3R^3$, $-C(NR^3)NR^3R^3$, -CHO, $-R^3CO$, $-SO_2R^3$, $-SOR^3$, $-PO(OR^3)_2$, $-PO(OR^3)$, $-CO_2H$, $-SO_3H$, $-PO_3H$, halogen and trihalomethyl;

each R^3 is independently selected from the group consisting of hydrogen, (C_1-C_6) alkyl, (C_5-C_{10}) aryl, five to sixteen membered heteroaryl, (C_6-C_{16}) arylalkyl and six to sixteen membered heteroarylalkyl; and

R is a core cyclic peptide or core antibiotic of a lipopeptide antibiotic, wherein said core cyclic peptide or core antibiotic is not of laspartomycin or polymyxin.

5. (Currently Amended) The antimicrobial sulfonamide derivative of Claim 4 in which R is the core cyclic peptide of ~~laspartomycin,~~ zaomycin, crystallomycin, aspartocin,

amphomycin, glumamycin, brevistin, cerexin A, cerexin B, Antibiotic A-30912, Antibiotic A-1437, Antibiotic A-54145, Antibiotic A-21978C or tsushimycin.

6. (Currently Amended) The antimicrobial sulfonamide derivative of Claim 4 in which R is the core antibiotic of ~~laspartomycin,~~ zaomycin, crystallomycin, aspartocin, amphomycin, glumamycin, brevistin, cerexin A, cerexin B, Antibiotic A-30912, Antibiotic A-1437, Antibiotic A-54145, Antibiotic A-21978C or tsushimycin.

7. (Currently Amended) The antimicrobial sulfonamide derivative of Claim 4 in which R is the core cyclic peptide of ~~laspartomycin,~~ aspartocin, Antibiotic A-30912, Antibiotic A-1437, Antibiotic A-54145 or Antibiotic A-21978C.

8. (Currently Amended) The antimicrobial sulfonamide derivative of Claim 4 in which R is the core antibiotic of ~~laspartomycin,~~ aspartocin, Antibiotic A-30912, Antibiotic A-1437, Antibiotic A54145 or Antibiotic A-21978C.

9. (Currently Amended) The antimicrobial sulfonamide derivative of Claim 4 in which R is the core cyclic peptide of ~~laspartomycin or~~ aspartocin.

10. (Currently Amended) The antimicrobial sulfonamide derivative of Claim 4 in which R is the core antibiotic of ~~laspartomycin or~~ aspartocin.

11. (Original) The antimicrobial sulfonamide derivative of Claim 4 in which m is 1.

12. (Original) The antimicrobial sulfonamide derivative of Claim 4 in which R^1 and R^4 are hydrogen.

13. (Currently Amended) The antimicrobial sulfonamide derivative of Claim 4 in which L is selected from the group consisting of:

(L1) 

(L2) 

(L3)  ; and

(L4) 

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

n is 0, 1, 2 or 3;

each S^1 is independently selected from the group consisting of hydrogen, $(C_1 - C_{10})$ alkyl optionally substituted with one or more of the same or different R^5 groups, $(C_1 - C_{10})$ heteroalkyl optionally substituted with one or more of the same or different R^5 groups, $(C_5$-$C_{10})$ aryl optionally substituted with one or more of the same or different R^5 groups, $(C_5$-$C_{15})$ arylaryl optionally substituted with one or more of the same or different R^5 groups,$(C_5$-$C_{15})$ biaryl optionally substituted with one or more of the same or different R^5 groups, five to ten membered heteroaryl optionally substituted with one or more of the same or different R^5 groups, $(C_6$-$C_{16})$ arylalkyl optionally substituted with one or more of the same or different R^5 groups and six to sixteen membered heteroarylalkyl optionally substituted with one or more of the same or different R^5 groups;

each R^5 is independently selected from the group consisting of $-OR^6$, $-SR^6$, $-NR^6R^6$, -CN, $-NO_2$, $-N_3$, $-C(O)OR^6$, $-C(O)NR^6R^6$, $-C(S)NR^6R^6$, $-C(NR^6)NR^6R^6$, -CHO, $-R^6CO$, $-SO_2R^6$, $-SOR^6$, $-PO(OR^6)_2$, $-PO(OR^6)$, $-CO_2H$, $-SO_3H$, $-PO_3H$, halogen and trihalomethyl;

each R^6 is independently selected from the group consisting of hydrogen, (C_1-C_6) alkyl, (C_5-C_{10}) aryl, five to sixteen membered heteroaryl, (C_6-C_{16}) arylalkyl and six to sixteen membered heteroarylalkyl; and

each K is independently selected from the group consisting of oxygen, nitrogen and sulfur.

14. (Original) The antimicrobial sulfonamide of Claim 13 in which each S^1 is independently a side-chain of a genetically encoded α-amino acid.

15. (Currently Amended) The antimicrobial sulfonamide of Claim 13 in which L is:



16. (Original) The antimicrobial sulfonamide derivative of Claim 15 in which each S^1 is independently a side-chain of a genetically encoded α-amino acid.

17. (Original) The antimicrobial sulfonamide derivative of Claim 15 in which n is 0.

18. (Currently Amended) The ~~compound~~ antimicrobial sulfonamide derivative of Claim 17 in which S^1 is hydrogen, ~~Y~~^{2}-Y is decan-yl and R is the core cyclic peptide of aspartocin.

19. (Original) The antimicrobial sulfonamide derivative of Claim 17 in which S^1 is $-CH_2-CO_2H$, $-CH_2-CH_2-CO_2H$, $-C(OH)H-CONH_2$, $-CH_2-CONH_2$ or $-CH_2-CH_2-CONH_2$ or a salt or hydrate thereof.

20. (Original) The antimicrobial sulfonamide derivative of Claim 17 in which S^1 is $-CH_2$-indol-2-yl or $-CH_2$-phenyl.

21. (Cancelled)

22. (Currently Amended) The antimicrobial sulfonamide derivative of Claim 13 in which L is:



wherein S^2 and S^3 are each independently a side chain of a genetically encoded α-amino acid.

23. (Cancelled)

24. (Original) The antimicrobial sulfonamide derivative of Claim 22 in which S^2 is hydrogen, $-CH_2$-indol-2-yl, $-CH_2-CONH_2$ or $-CH_2-CH_2-CONH_2$ and S^3 is $-CH_2-CO_2H$, $-CH_2-CH_2-CO_2H$ or a salt or hydrate thereof.

25. (Original) The antimicrobial sulfonamide derivative of Claim 22 in which S^2 is $-CH_2-CO_2H$, $-CH_2-CH_2-CO_2H$ or a salt or hydrate thereof and S^3 is $-C(OH)H-CONH_2$.

26. (Currently Amended) The antimicrobial sulfonamide derivative of Claim 13 in which L is:



wherein S^2, S^3, and S^4 are each independently a side chain of a genetically encoded α-amino acid.

27. (Cancelled)

28. (Original) The antimicrobial sulfonamide derivative of Claim 26 in which S^2 is -CH_2-indol-2-yl, S^3 is -CH_2-$CONH_2$ or -CH_2-CH_2-$CONH_2$ and S^4 is -CH_2-CO_2H, -CH_2-CH_2-CO_2H or a salt or hydrate thereof.

29. (Original) The antimicrobial sulfonamide derivative of Claim 26 in which S^2 is -CH_2-indol-2-yl, S^3 is -CH_2-CO_2H, CH_2-CH_2-CO_2H or a salt or hydrate thereof and S4 is -CH_2-$CONH_2$, -CH_2-CH_2-$CONH_2$ or -C(OH)H-$CONH_2$.

30. (Original) The antimicrobial sulfonamide derivative of Claim 4 in which m is 0.

31. (Original) The antimicrobial sulfonamide derivative of Claim 30 in which R^4 is hydrogen.

32. (Currently Amended) The antimicrobial sulfonamide derivative of Claim 30 in which R is the core antibiotic of ~~laspartomycin or~~ aspartocin.

33. (Currently Amended) The antimicrobial sulfonamide derivative of ~~Claim 32~~ Claim 30 in which R is the core cyclic peptide of ~~laspartomycin or~~ aspartocin.

34. (Currently Amended) A pharmaceutical composition comprising ~~a compound~~ an antimicrobial sulfonamide derivative according to Claim 4 and a pharmaceutically acceptable adjuvant, excipient, carrier or diluent.

35. (Original) A method for treating or preventing a microbial infection, said method comprising the step of administering to a subject a therapeutically effective amount of a compound according to Claim 4 or a therapeutically effective amount of a pharmaceutical composition according to Claim 34.

36. (Currently Amended) A method of inhibiting microbial growth, said method comprising the step of administering to a microbe an antimicrobially effective amount of ~~a compound~~ an antimicrobial sulfonamide derivative according to Claim 4 or an antimicrobially effective amount of a pharmaceutical composition according to Claim 34.

37. (Currently Amended) A method for making an antimicrobial sulfonamide derivative comprising sulfonylating ~~an~~ a core antibiotic or core cyclic peptide with a lipophilic sulfonyl derivative, thereby providing ~~a~~ an antimicrobial sulfonamide derivative.

38. (Original) The method of Claim 37 in which the lipophilic sulfonyl derivative is a activated lipophilic sulfonyl ester or a lipophilic sulfonyl halide.

39. (Original) The method of Claim 38 in which the activated lipophilic sulfonyl ester is a lipophilic hydroxybenzotriazole ester.

40. (Currently Amended) The method of ~~Claim 39~~ Claim 38 in which the lipophilic sulfonyl halide is a lipophilic sulfonyl chloride.

41. (Currently Amended) A method for making an antimicrobial sulfonamide derivative comprising:

sulfonylating a linker with a lipophilic sulfonyl compound, thereby providing a lipophilic sulfonamide linker; and

covalently attaching the lipophilic sulfonamide linker to ~~an~~ a core antibiotic or core cyclic peptide wherein said core cyclic peptide or core antibiotic is not of polymyxin, thereby yielding ~~a~~ an antimicrobial sulfonamide derivative.

42. (Currently Amended) A method for making an antimicrobial sulfonamide derivative comprising:

covalently attaching a linker to ~~an~~ a core antibiotic or core cyclic peptide, thereby providing an linker core antibiotic or linker core cyclic peptide; and

sulfonylating the linker core antibiotic or linker core cyclic peptide with a lipophilic sulfonyl derivative, thereby yielding ~~a~~ an antimicrobial sulfonamide derivative.